Free Trial
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

$15.91
+0.02 (+0.13%)
(As of 09/6/2024 ET)
Today's Range
$15.67
$15.98
50-Day Range
$14.57
$17.30
52-Week Range
$13.16
$17.92
Volume
473,703 shs
Average Volume
513,533 shs
Market Capitalization
$5.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.59

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
16.9% Upside
$18.59 Price Target
Short Interest
Bearish
5.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Bausch + Lomb in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$505,035 Bought Last Quarter
Proj. Earnings Growth
43.33%
From $0.60 to $0.86 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.87 out of 5 stars

Medical Sector

358th out of 910 stocks

Ophthalmic Goods Industry

6th out of 8 stocks

BLCO stock logo

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

BLCO Stock News Headlines

Say Goodbye to the US Dollar
The warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late...
BLCO Sep 2024 17.500 put (BLCO240920P00017500)
BLCO Sep 2024 15.000 put
Bausch + Lomb Insider Ups Holding During Year
Say Goodbye to the US Dollar
The warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late...
Bausch + Lomb: Hold Rating Amid Growth and Separation Uncertainty
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/31/2024
Today
9/07/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Medical Equipment
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.59
High Stock Price Target
$23.00
Low Stock Price Target
$15.50
Potential Upside/Downside
+16.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-5.74%

Debt

Sales & Book Value

Annual Sales
$4.50 billion
Cash Flow
$1.85 per share
Book Value
$18.69 per share

Miscellaneous

Free Float
N/A
Market Cap
$5.60 billion
Optionable
Optionable
Beta
0.46
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Osama A. Eldessouky (Age 52)
    Executive VP & CFO
    Comp: $1.09M
  • Dr. Yehia Hashad M.D. (Age 57)
    Executive VP of Research & Development and Chief Medical officer
    Comp: $1.09M
  • Mr. Brenton L. Saunders J.D.Mr. Brenton L. Saunders J.D. (Age 54)
    CEO & Chairman
  • Mr. Alan Waterhouse CPFA (Age 64)
    MBA, Executive VP and Chief Supply Chain & Operations Officer
  • Mr. Frederick J. Munsch (Age 53)
    Senior VP, Controller & Chief Accounting Officer
  • Mr. A. Robert D. Bailey (Age 61)
    Executive VP & Chief Legal Officer
  • Mr. Jonathon L. Kellerman
    Chief Compliance Officer
  • T.J. Crawford
    Chief Communications Officer
  • Dr. Manisha A. Narasimhan Ph.D. (Age 47)
    Chief Corporate Development & Digital Officer
  • Ms. Asli Gevgilili
    Executive VP & Chief Human Resources Officer

BLCO Stock Analysis - Frequently Asked Questions

How have BLCO shares performed this year?

Bausch + Lomb's stock was trading at $17.06 at the beginning of 2024. Since then, BLCO stock has decreased by 6.7% and is now trading at $15.91.
View the best growth stocks for 2024 here
.

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) released its earnings results on Wednesday, July, 31st. The company reported $0.13 earnings per share for the quarter, hitting analysts' consensus estimates of $0.13. The company's revenue was up 17.5% compared to the same quarter last year.

When did Bausch + Lomb IPO?

Bausch + Lomb (BLCO) raised $788 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Top institutional investors of Bausch + Lomb include Whitebox Advisors LLC (0.44%), Clearline Capital LP (0.20%), Point72 Europe London LLP (0.19%) and Point72 Asset Management L.P. (0.18%).
View institutional ownership trends
.

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners